Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Cilomilast. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PDE4B known ✓ | Q07343 | 20/20 | 1.00 |
| ▸ | PDE4A known ✓ | P27815 | 19/20 | 1.00 |
| ▸ | PDE4C known ✓ | Q08493 | 19/20 | 1.00 |
| ▸ | PDE4D known ✓ | Q08499 | 19/20 | 1.00 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Cilomilast SCHEMBL27516 | 1.00 | PDE4B (1.00) | PDE4BPDE4APDE4CPDE4D | |
| Cilomilast SCHEMBL27515 | 1.00 | PDE4B (1.00) | PDE4BPDE4APDE4CPDE4D | |
| Cilomilast SCHEMBL26372 | 1.00 | PDE4B (1.00) | PDE4BPDE4APDE4CPDE4D | |
| Cilomilast SCHEMBL5975855 | 1.00 | PDE4B (1.00) | PDE4BPDE4APDE4CPDE4D | |
| Cilomilast SCHEMBL6904030 | 0.99 | PDE4B (0.98) | PDE4BPDE4APDE4CPDE4D | |
| Cilomilast SCHEMBL29107422 | 0.99 | PDE4B (0.98) | PDE4BPDE4APDE4CPDE4D | |
| Cilomilast SCHEMBL7130621 | 0.99 | PDE4B (0.98) | PDE4BPDE4APDE4CPDE4D | |
| Cilomilast SCHEMBL7130626 | 0.99 | PDE4B (0.98) | PDE4BPDE4APDE4CPDE4D | |
| Cilomilast SCHEMBL7124080 | 0.97 | PDE4B (0.94) | PDE4BPDE4APDE4CPDE4D | |
| SCHEMBL28381093 | 0.96 | PDE4B (0.92) | PDE4BPDE4APDE4CPDE4D |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 67 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-106390128-B | Use of beta-adrenergic inverse agonists for smoking cessation | 伊沃恩有限公司 | 2022-07-08 | — | — | CN | claimed |
| EP-2152341-B2 | ATOMIZER IN THE FORM OF AN INHALER FOR MEDICAL AEROSOL THERAPY | BOEHRINGER INGELHEIM PHARMA (DE) | 2025-04-02 | — | — | EP | disclosed |
| US-12258316-B2 | Biphenyl compounds useful as muscarinic receptor antagonists | THERAVANCE BIOPHARMA R&D IP, LLC (US) | 2025-03-25 | — | — | US | disclosed |
| CN-115916305-B | Multi-carrier medicament dispenser | 陆品公司 | 2025-03-21 | — | — | CN | disclosed |
| EP-4419502-A2 | COMPOUNDS AND METHODS FOR THE TREATMENT OF DERMAL AND OCULAR DISORDERS | AZURA OPHTHALMICS LTD (IL) | 2024-08-28 | — | — | EP | disclosed |
| EP-4309653-A1 | THERAPEUTIC COMPOUNDS AND COMPOSITIONS | Exithera Pharmaceuticals Inc. (US) | 2024-01-24 | — | — | EP | disclosed |
| CN-116782911-A | Therapeutic compounds, compositions, and methods of use thereof | 艾克赛特赫拉制药有限责任公司 | 2023-09-19 | — | — | CN | disclosed |
| EP-3681504-B1 | METHODS OF DETECTION USING X-RAY FLUORESCENCE | ICAGEN INC (US) | 2023-08-23 | — | — | EP | disclosed |
| EP-4213857-A1 | THERAPEUTIC COMPOUNDS, COMPOSITIONS, AND METHODS OF USE THEREOF | Exithera Pharmaceuticals Inc. (US) | 2023-07-26 | — | — | EP | disclosed |
| CN-116444506-A | Therapeutic compounds and compositions | 艾克赛特赫拉制药有限责任公司 | 2023-07-18 | — | — | CN | disclosed |
| US-7442687-B2 | 2-polycyclic propynyl adenosine analogs having A2A agonist activity | THE UNIVERSITY OF VIRGINIA PATENT FOUNDATION (US) | 2008-10-28 | — | — | US | disclosed |
| US-20080207644-A1 | Therapeutic materials and methods | ARIAD PHARMACEUTICALS, INC. | 2008-08-28 | — | — | US | disclosed |
| US-7396825-B2 | Agonists of A2A adenosine receptors for treatment of diabetic nephropathy | UNIVERSITY OF VIRGINIA PATENT FOUNDATION (US) | 2008-07-08 | — | — | US | disclosed |
| US-7396825-B2 | Agonists of A2A adenosine receptors for treatment of diabetic nephropathy | UNIVERSITY OF VIRGINIA PATENT FOUNDATION (US) | 2008-07-08 | — | — | US | disclosed |
| EP-1849468-A2 | Pharmaceutical composition of a pde4 or a pde3/4 inhibitor and a histamine receptor antagonist | Nycomed GmbH (DE) | 2007-10-31 | — | — | EP | disclosed |
| US-20070208181-A1 | BENZYLATED PDE4 INHIBITORS | INFLAZYME PHARMACEUTICALS LTD. (CA) | 2007-09-06 | — | — | US | disclosed |
| US-20070208181-A1 | BENZYLATED PDE4 INHIBITORS | INFLAZYME PHARMACEUTICALS LTD. (CA) | 2007-09-06 | — | — | US | disclosed |
| US-20040171597-A1 | Anti-inflammatory 17.beta.-carbothioate ester derivatives of androstane with a cyclic ester group in position 17.alpha | GLAXO GROUP LIMITED (GB) | 2004-09-02 | — | — | US | disclosed |
| WO-2004047817-A1 | PDE4 AND PDE3/4 INHIBITORS FOR USE IN THE TREATMENT OF CACHEXIA | ALTANA PHARMA AG (DE) | 2004-06-10 | — | — | WO | disclosed |
| WO-2003024488-A2 | COMBINATION OF A PDE INHIBITOR AND A LEUKOTRIENE RECEPTOR ANTAGONIST | ALTANA PHARMA AG (DE) | 2003-03-27 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040171597-A1 | Anti-inflammatory 17.beta.-carbothioate ester derivatives of androstane with a cyclic ester group in position 17.alpha | NR5A1, HSD17B7, HSD17B1 | PDE4B 2371/4885PDE4A 1933/4885PDE4C 2570/4885 |
| US-20080207644-A1 | Therapeutic materials and methods | DUSP4, MAPKAP1, MAPK4 | PDE4B 27/4885PDE4A 22/4885PDE4C 106/4885 |
| US-12258316-B2 | Biphenyl compounds useful as muscarinic receptor antagonists | CHRM2, CHRM1, CHRM3 | PDE4B 827/4885PDE4A 1337/4885PDE4C 1520/4885 |
| US-20070208181-A1 | BENZYLATED PDE4 INHIBITORS | PDE4B, PDE4A, PDE3B | PDE4B 1/4885PDE4A 2/4885PDE4C 4/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.